Sequana Medical NV logo

SEQUA - Sequana Medical NV Share Price

€8.34 -0.5  -5.2%

Last Trade - 4:35pm

Sector
Healthcare
Size
Small Cap
Market Cap £141.0m
Enterprise Value £131.0m
Revenue £1.00m
Position in Universe 468th / 846
Bullish
Bearish
Unlock SEQUA Revenue
Momentum
Relative Strength (%)
1m -16.1%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -29.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 1.68 1.49 1.30 1.03 0.97 1.00 1.27 -12.9%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, SequanaMedical NV revenues increased 44% to EUR595K. Net lossapplicable to common stockholders increased 31% to EUR9.6M.Revenues reflect Germany segment increase of 44% toEUR399K. Higher net loss reflects Clinical Affairs increasefrom EUR1.5M to EUR3.1M (expense), Engineering increase of44% to EUR771K (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

SEQUA Revenue Unlock SEQUA Revenue

Net Income

SEQUA Net Income Unlock SEQUA Revenue

Normalised EPS

SEQUA Normalised EPS Unlock SEQUA Revenue

PE Ratio Range

SEQUA PE Ratio Range Unlock SEQUA Revenue

Dividend Yield Range

SEQUA Dividend Yield Range Unlock SEQUA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
SEQUA EPS Forecasts Unlock SEQUA Revenue
Profile Summary

Sequana Medical NV is a Belgium-based company, which manufactures medical devices. The Company focuses mainly on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites and other fluid imbalance disorders. Sequana Medical NV provides alfapump, which is an implantable, programmable, wireless-charged and battery-powered system that is CE-marking for the management of refractory ascites due to liver cirrhosis and malignant ascites. Over 650 alfapump systems have been implanted. Apart from the Alfapump, the Company also aims to develop a direct sodium removal (DSR) therapy, which is a propriety approach to the treatment of volume overload in heart failure.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated October 1, 2018
Public Since February 1, 2018
No. of Shareholders: n/a
No. of Employees: 45
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Euronext - Brussels
Shares in Issue 18,438,435
Free Float (0.0%)
Eligible for
ISAs
SIPPs
SEQUA Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for SEQUA
Upcoming Events for SEQUA
Frequently Asked Questions for Sequana Medical NV
What is the Sequana Medical NV share price?

As of 4:35pm, shares in Sequana Medical NV are trading at €8.34, giving the company a market capitalisation of £141.0m. This share price information is delayed by 15 minutes.

How has the Sequana Medical NV share price performed this year?

Shares in Sequana Medical NV are currently trading at €8.34 and the price has moved by 33.33% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Sequana Medical NV price has moved by 27.44% over the past year.

What are the analyst and broker recommendations for Sequana Medical NV?

Of the analysts with advisory recommendations for Sequana Medical NV, there are there are currently 2 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Sequana Medical NV is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Sequana Medical NV next release its financial results?

Sequana Medical NV is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Sequana Medical NV dividend yield?

Sequana Medical NV does not currently pay a dividend.

Does Sequana Medical NV pay a dividend?

Sequana Medical NV does not currently pay a dividend.

When does Sequana Medical NV next pay dividends?

Sequana Medical NV does not currently pay a dividend.

How do I buy Sequana Medical NV shares?

To buy shares in Sequana Medical NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Sequana Medical NV?

Shares in Sequana Medical NV are currently trading at €8.34, giving the company a market capitalisation of £141.0m.

Where are Sequana Medical NV shares listed? Where are Sequana Medical NV shares listed?

Here are the trading details for Sequana Medical NV:

Country of listing: Belgium
Exchange: BRU
Ticker Symbol: SEQUA
What kind of share is Sequana Medical NV?

Based on an overall assessment of its quality, value and momentum, Sequana Medical NV is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Sequana Medical NV share price forecast 2021?

Shares in Sequana Medical NV are currently priced at €8.34. At that level they are trading at 52.27% discount to the analyst consensus target price of 0.00.

Analysts covering Sequana Medical NV currently have a consensus Earnings Per Share (EPS) forecast of -1.33 for the next financial year.

How can I tell whether the Sequana Medical NV share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sequana Medical NV. Over the past six months, the relative strength of its shares against the market has been 26.72%. At the current price of €8.34, shares in Sequana Medical NV are trading at 22.43% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Sequana Medical NV PE Ratio?

We were not able to find PE ratio data for Sequana Medical NV.

Who are the key directors of Sequana Medical NV?

Sequana Medical NV's management team is headed by:

Pierre Chauvineau - NEC
Ian Crosbie - CEO
Rudy Dekeyser - NED
Erik Amble - NED
Wim Ottevaere - NID
Kirsten Van Bockstaele - CFO
Gijs Klarenbeek - OTH
Martijn Blom - OTH
Timur Resch - VPR
Dirk Fengels - VPR
Who are the major shareholders of Sequana Medical NV?

Here are the top five shareholders of Sequana Medical NV based on the size of their shareholding:

NeoMed Management AS Venture Capital
Percentage owned: 23.16% (4.27m shares)
Life Sciences Partners Venture Capital
Percentage owned: 9.25% (1.71m shares)
Government of Flanders Government Agency
Percentage owned: 8.04% (1.48m shares)
SFPI-FPIM Investment Advisor
Percentage owned: 6.73% (1.24m shares)
Newton Biocapital SA Venture Capital
Percentage owned: 5.75% (1.06m shares)
Similar to SEQUA
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.